Estropipate
Ogen (estropipate) is a small molecule pharmaceutical. Estropipate was first approved as Ogen 5 on 1982-01-01. It is used to treat hot flashes, hypogonadism, menopause, menorrhagia, and premature menopause amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Ogen (discontinued: Estropipate, Ogen, Ortho-est)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| estropipate | ANDA | 2012-03-14 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 1 | — | — | 1 | 1 | 3 |
| Contraception | D003267 | — | — | — | — | — | 1 | 1 | 2 |
| Physiological sexual dysfunction | D012735 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | — | 2 | — | — | 4 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | 4 | 5 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | — | — | 1 | 4 |
| Syndrome | D013577 | — | — | — | 3 | — | — | 1 | 4 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | 2 | — | — | — | 2 |
| Hot flashes | D019584 | — | — | — | 1 | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | — | 1 | — | — | — | 1 |
| Atrophy | D001284 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female infertility | D007247 | EFO_0008560 | N97 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | — | — | 1 | 1 |
| Amenorrhea | D000568 | — | N91.2 | — | — | — | — | 1 | 1 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | — | — | — | 1 | 1 |
| Premature menopause | D008594 | — | E28.31 | — | — | — | — | 1 | 1 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | — | — | — | 1 | 1 |
| Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
| Lacerations | D022125 | — | — | — | — | — | — | 1 | 1 |
| Female genital neoplasms | D005833 | — | — | — | — | — | — | 1 | 1 |
| Postmenopause | D017698 | — | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estropipate |
| INN | — |
| Description | Estropipate is a steroid sulfate and a piperazinium salt. It is functionally related to an estrone. |
| Classification | Small molecule |
| Drug class | estrogens; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1CNCCN1.C[C@]12CC[C@@H]3c4ccc(OS(=O)(=O)O)cc4CC[C@H]3[C@@H]1CCC2=O |
Identifiers
| PDB | — |
| CAS-ID | 7280-37-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200980 |
| ChEBI ID | — |
| PubChem CID | 5284555 |
| DrugBank | DB04574 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Estropipate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 104 documents
View more details
Safety
Black-box Warning
Black-box warning for: Estropipate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
731 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use